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Introduction {#cam41397-sec-0001}
============

Thyroid cancer (TC) is one of the most common cancers around the world [1](#cam41397-bib-0001){ref-type="ref"}. Although thyroid nodules were usually diagnosed as benign, 5\~15% proved to be malignant [2](#cam41397-bib-0002){ref-type="ref"}, [3](#cam41397-bib-0003){ref-type="ref"}. Fine‐needle aspiration (FNA) biopsies were the common way to determine the malignancy of thyroid nodules. However, 15\~30% of aspirations reported an indeterminate cytologic finding [4](#cam41397-bib-0004){ref-type="ref"}, [5](#cam41397-bib-0005){ref-type="ref"}. Most of these patients were recommended for a diagnostic thyroid surgery, but only 15\~25% proved malignant [6](#cam41397-bib-0006){ref-type="ref"}. Thus, the surgery was unnecessary for a significant number of patients, which were exposed to a 2\~10% risk of serious surgical complications. Moreover, lifetime levothyroxine supplementation and additional medical costs were also required [7](#cam41397-bib-0007){ref-type="ref"}. In clinical practice, it had a critical need to increase the diagnostic accuracy for TC.

Recently, several molecular signatures have been identified to improve TC diagnosis [8](#cam41397-bib-0008){ref-type="ref"}, [9](#cam41397-bib-0009){ref-type="ref"}. However, most signatures were limited in the sample size and absence of a specific diagnostic formula and cross‐validation. With the development of high‐throughput gene detection technology, gene expression profiles were available to identify more novel and robust biomarkers. On the other hand, diverse biological algorithms provided the possibility to integrate the samples in different batches and construct a more practical diagnostic or prognostic signature [10](#cam41397-bib-0010){ref-type="ref"}. In this study, we integrated a large number of samples and developed and validated an individualized diagnostic signature in TC.

Method {#cam41397-sec-0002}
======

Data collection {#cam41397-sec-0003}
---------------

Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo/>) was searched for related gene expression profiles from inception to 1 October 2017. Datasets were included if fulfilled the following criteria: containing both TC samples and nontumor samples (adjacent normal tissues, thyroid adenoma, or healthy controls); based on the chip platform of Affymetrix Human Genome U133 Array (GPL96, GPL570, or GPL571); a sample size of more than 10. The datasets with a sample size of more than 50 and at least 20 nontumor samples were merged into one set for signature identification (training set), while the remaining were pooled into one set for signature validation (test set). Moreover, another RNA‐sequencing dataset from The Cancer Genome Atlas (TCGA) (<https://cancergenome.nih.gov/>) was also selected as an independent validation set.

Data preprocessing {#cam41397-sec-0004}
------------------

Normalized gene expression profiles were downloaded by an ftp method (<http://ftp://ftp.ncbi.nlm.nih.gov/geo/series/>). The probe IDs were matched to gene symbols using the Affymetrix annotation files (<http://www.affymetrix.com>). When multiple probes matched to an identical gene symbol, we took the average value of expression values across multiple probe IDs to represent the corresponded gene symbol [11](#cam41397-bib-0011){ref-type="ref"}.

Differentially expressed genes (DEGs) screening {#cam41397-sec-0005}
-----------------------------------------------

Linear model was used to screen the DEGs between tumor and nontumor samples in each included dataset of the training set. The false discovery rate (FDA) \<0.05 and \|log~2~ fold change (FC)\| \>0.585 were chosen as the cutoff criteria.

Signature construction {#cam41397-sec-0006}
----------------------

In training set, the most frequent DEGs among the included datasets were selected, and the gene expression level in a specific sample underwent pairwise comparison with generate a score for each gene pair. If the first gene of a gene pair had a higher expression value than the second gene, a gene‐pair score of 1 was assigned; otherwise, the gene‐pair score was 0. Then, a LASSO penalized generalized linear model was used in the training set to identify significant gene pairs [12](#cam41397-bib-0012){ref-type="ref"}. The penalty parameter was estimated by 10‐fold cross‐validation at 1 standard error (SE) beyond the minimum partial likelihood deviance.

Signature evaluation and validation {#cam41397-sec-0007}
-----------------------------------

The coefficients of significant gene pairs in the model were extracted to calculate a diagnostic score for each sample in the training set, test set, and TCGA set. Receiver operating characteristic (ROC) curves and area under ROC curve (AUC) were used to evaluate the diagnostic ability of the signature score, validate it in different sets, and compare it with other molecular signatures.

Statistical analysis {#cam41397-sec-0008}
--------------------

All statistical analyses were performed using R software (version 3.4.2, <https://www.r-project.org/>). DEG analysis was conducted with limma (version 3.6) package. The generalized linear model was constructed with glmnet package (version 2.0‐13). ROC analysis was performed with ROCR (version 1.0‐7) package. A two‐sided *P* value \<0.05 was considered statistically significant.

Results {#cam41397-sec-0009}
=======

Characteristics of included datasets {#cam41397-sec-0010}
------------------------------------

Thirteen GEO datasets and one TCGA dataset were identified with a total of 1246 samples (925 tumor samples and 321 nontumor samples) (Table [1](#cam41397-tbl-0001){ref-type="table-wrap"}). Ten microarray datasets were based on the platform of GPL570, and three on GPL96. Five datasets (GSE27155, GSE33630, GSE35570, GSE60542, and GSE82208) were merged into a training set with a total of 263 tumor and 172 nontumor samples. The remaining eight datasets (GSE29265, GSE3467, GSE3678, GSE53157, GSE5364, GSE58545, GSE6004, and GSE65144) were pooled into a test set with a total of 157 tumor and 90 nontumor samples. Another independent validation set of TCGA had a total of 505 tumor and 59 nontumor samples.

###### 

Details about the datasets used in this study

  Accession                    Year   Area        Platform        Number of samples         
  ---------------------------- ------ ----------- --------------- ------------------- ----- ----
  Training set                                                                              
  GSE27155                     2011   USA         GPL96           99                  78    21
  GSE33630                     2012   Belgium     GPL570          105                 60    45
  GSE35570                     2015   Poland      GPL570          116                 65    51
  GSE60542                     2015   Belgium     GPL570          63                  33    30
  GSE82208                     2017   Poland      GPL570          52                  27    25
  Test set                                                                                  
  GSE29265                     2012   Belgium     GPL570          49                  29    20
  GSE3467                      2005   USA         GPL570          18                  9     9
  GSE3678                      2006   USA         GPL570          14                  7     7
  GSE53157                     2013   Portugal    GPL570          27                  24    3
  GSE5364                      2008   Singapore   GPL96           51                  35    16
  GSE58545                     2015   Poland      GPL96           45                  27    18
  GSE6004                      2006   USA         GPL570          18                  14    4
  GSE65144                     2015   USA         GPL570          25                  12    13
  Independent validation set                                                                
  TCGA                         2015   USA         IlluminaHiSeq   564                 505   59
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Signature construction and evaluation {#cam41397-sec-0011}
-------------------------------------

In training set, 115 genes were identified as DEGs among at least four included datasets (Figure [S1](#cam41397-sup-0001){ref-type="supplementary-material"}). These genes were used to construct 6555 gene pairs. The LASSO penalized generalized linear model identified 19 significant gene pairs (consisting of 26 genes), which showed an obviously different distribution in tumor and nonsample samples (Fig. [1](#cam41397-fig-0001){ref-type="fig"}). Then, a diagnostic score was developed based on these gene pairs and their coefficients in the model (Table [2](#cam41397-tbl-0002){ref-type="table-wrap"}). The score showed a good diagnostic ability for TC (AUC = 0.976) (Fig. [2](#cam41397-fig-0002){ref-type="fig"}). Subgroup analyses also showed consistent results when considering the type of nontumor samples and microarray platforms.

![Heatmap of the gene‐pair scores in tumor and nontumor samples of training set.](CAM4-7-1135-g001){#cam41397-fig-0001}

###### 

Signature information

  Gene pair 1   Full name                                                   Gene pair 2   Full name                                                                                Coefficient
  ------------- ----------------------------------------------------------- ------------- ---------------------------------------------------------------------------------------- --------------
  CA4           Carbonic anhydrase IV                                       CDH3          Cadherin 3, type 1, P‐cadherin                                                           −0.343957681
  CA4           Carbonic anhydrase IV                                       DPP4          Dipeptidyl‐peptidase 4                                                                   −0.414152857
  DPP4          Dipeptidyl‐peptidase 4                                      SMAD9         SMAD family member 9                                                                     0.198178763
  GLRB          Glycine receptor, beta                                      SEMA3D        Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3D   0.213058352
  GLT8D2        Glycosyltransferase 8 domain containing 2                   IER2          Immediate early response 2                                                               0.054809905
  GLUL          Glutamate‐ammonia ligase                                    TFF3          Trefoil factor 3                                                                         0.106305040
  HSPA5         Heat shock 70 kDa protein 5                                 TFF3          Trefoil factor 3                                                                         0.137164218
  ID1           Inhibitor of DNA binding 1                                  TPO           Thyroid peroxidase                                                                       0.133836321
  ITIH5         Interalpha‐trypsin inhibitor heavy chain family, member 5   LRP4          Low‐density lipoprotein receptor‐related protein 4                                       −0.449239654
  KRT19         Keratin 19                                                  LMOD1         Leiomodin 1                                                                              0.166685729
  KRT19         Keratin 19                                                  LRP1B         Low‐density lipoprotein receptor‐related protein 1B                                      0.026410689
  LMOD1         Leiomodin 1                                                 SLC34A2       Solute carrier family 34, member 2                                                       −0.134480682
  LRP1B         Low‐density lipoprotein receptor‐related protein 1B         LRP4          Low‐density lipoprotein receptor‐related protein 4                                       −0.180802140
  LRP1B         Low‐density lipoprotein receptor‐related protein 1B         MYEF2         Myelin expression factor 2                                                               −1.070962895
  LRP1B         Low‐density lipoprotein receptor‐related protein 1B         SLMO1         Slowmo homolog 1                                                                         −0.158658033
  LRP4          Low‐density lipoprotein receptor‐related protein 4          TNFRSF11B     Tumor necrosis factor receptor superfamily, member 11b                                   0.149105475
  NELL2         NEL‐like 2                                                  TCEAL2        Transcription elongation factor A (SII)‐like 2                                           0.178969566
  QPCT          Glutaminyl‐peptide cyclotransferase                         TNFRSF11B     Tumor necrosis factor receptor superfamily, member 11b                                   0.692483617
  TCEAL2        Transcription elongation factor A (SII)‐like 2              TRAPPC6A      Trafficking protein particle complex 6A                                                  −0.229715917
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![Receiver operating characteristic (ROC) curves and area under ROC curve (AUC) of the diagnostic signature in training set.](CAM4-7-1135-g002){#cam41397-fig-0002}

Signature validation {#cam41397-sec-0012}
--------------------

We also constructed the same 19 gene pairs in the test set and TCGA set. The coefficients of the 19 gene pairs in the model of training set were extracted to calculate a diagnostic score for each sample in test set and TCGA set. The score also showed a good diagnostic ability in both test set (AUC = 0.960) and TCGA set (AUC = 0.979) (Fig. [3](#cam41397-fig-0003){ref-type="fig"}).

![Receiver operating characteristic (ROC) curves and area under ROC curve (AUC) of the diagnostic signature in test set.](CAM4-7-1135-g003){#cam41397-fig-0003}

Comparison with other molecular signatures {#cam41397-sec-0013}
------------------------------------------

A 7‐gene signature and 10‐gene signature were published recently, both of which showed a good diagnostic ability for thyroid nodule malignancy [13](#cam41397-bib-0013){ref-type="ref"}, [14](#cam41397-bib-0014){ref-type="ref"}. As all nontumor samples in GSE82208 were obtained from thyroid nodules and diagnosed as follicular adenoma, this dataset was selected to reevaluate the two signatures using a logistics regression model. In result, the gene‐pair signature (AUC = 0.933) showed a better diagnostic ability than the 7‐gene signature (AUC = 0.886) and 10‐gene signature (AUC = 0.892) (Fig. [4](#cam41397-fig-0004){ref-type="fig"}).

![Receiver operating characteristic (ROC) curves and area under ROC curve (AUC) of different signatures in diagnosing thyroid nodules.](CAM4-7-1135-g004){#cam41397-fig-0004}

Discussion {#cam41397-sec-0014}
==========

With the development of microarray and RNA‐sequencing technology, we were entering a new era of big biological data. A tremendous amount of genomic information was detected in individual samples, which promoted the identification of novel biomarkers, therapeutic targets, and potential pathogenesis. However, most studies were limited in the sample size, and it was difficult to integrate the samples in different sets for batch effects. The TCGA plan has finished RNA sequencing of a relatively large number of tumor samples in multiple cancers. LncRNA and mRNA prognostic signatures of TC have been developed using the TCGA data [15](#cam41397-bib-0015){ref-type="ref"}, [16](#cam41397-bib-0016){ref-type="ref"}. However, few studies focused on the microarray and RNA‐sequencing data to identify diagnostic signatures in TC. The 167‐gene model by Alexander et al. was the first signature based on TC microarray data [17](#cam41397-bib-0017){ref-type="ref"}. It showed a good diagnostic ability, but it was really difficult for clinical practice, considering the lack of a specific diagnostic formula and cross‐validation based on large‐scale samples and multiple platforms.

Multiple microarray platforms occurred in recent years. Thereinto, Affymetrix Human Genome U133 Arrays were well illustrated and widely used. In this study, we reviewed all TC studies based on the Affymetrix U133 platform in GEO database and selected those with tumor and nontumor samples for further analyses. Datasets with a relatively large sample size were included for DEGs analysis. Considering the significant heterogeneity between studies, we chose the most frequent DEGs among individual studies as candidate genes. In gene ontology analysis, these DEGs showed an association with thyroid hormone metabolic process (Figure [S2](#cam41397-sup-0001){ref-type="supplementary-material"}). Subsequently, we constructed 6555 gene pairs with the 115 DEGs. The signature consisting of 19 gene pairs showed a good diagnostic ability for TC. The 26 genes constituting the gene pairs also related with multiple biological processes, especially estrogen‐related process which was involved in the pathogenesis of TC [18](#cam41397-bib-0018){ref-type="ref"}, [19](#cam41397-bib-0019){ref-type="ref"} (Figure [S3](#cam41397-sup-0001){ref-type="supplementary-material"}). The gene‐pair signature reflected the expression imbalance of estrogen‐related genes, which could make significant effects on the development of TC.

This gene‐pair‐based method had an important advantage because the score was calculated based entirely on the gene expression profile of an individual sample and could be used in an individualized manner without the need for considering the batch effects [20](#cam41397-bib-0020){ref-type="ref"}, [21](#cam41397-bib-0021){ref-type="ref"}. By this method, we were able to integrate small‐scale studies into one large set, which increased the utilizing efficiency of public biological data. Furthermore, considering the heterogeneity between different gene detection technologies, we evaluated the robustness of our signature by a RNA‐sequencing dataset, and the signature had a stable performance. We also used the same data to compare the signature with other molecular signatures, and the signature showed a higher ability in diagnosing thyroid nodules.

In clinical application, it was very promising to develop a diagnostic kit which could measure the expression levels of 26 genes in the 19 gene pairs. Then, the sample could be diagnosed as malignant or benign according to the signature score and the threshold.

The limitations should be acknowledged for our study. First, this study was retrospective designed, although we tried to include as many datasets as possible and took a rigorous validation for our signature. Second, the gene‐pair method was an individualized method, but not all batch effects could be addressed, and some might remain.

In conclusion, our study developed and validated an individualized diagnostic signature in thyroid cancer. Large‐scale prospective studies were needed to further validate its diagnostic ability.
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**Figure S1.** Distribution of differentially expressed genes in five included datasets of the training set.**Figure S2.** Heatmap of enriched biological processes across the differentially expressed genes (colored by *P* values).**Figure S3.** Heatmap of enriched biological processes across the 26 genes in the signature (colored by *P* values).

###### 

Click here for additional data file.
